HARROW, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.53 USD | +5.30% |
|
+0.77% | -5.98% |
| Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
| Mar. 22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to Harrow's Third ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.53
USD
Average target price
26.65
USD
Spread / Average Target
+153.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.98% | 372M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Transcript : Harrow, Inc., Q3 2023 Earnings Call, Nov 13, 2023
